Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF NOVEMBER 21, 2004 FBO #1091
SPECIAL NOTICE

A -- Chemical Optimization and Preclinical Development of Molecular-Targeted Anticancer Drug Leads

Notice Date
11/19/2004
 
Notice Type
Special Notice
 
NAICS
325411 — Medicinal and Botanical Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
 
ZIP Code
21702
 
Solicitation Number
Reference-Number-BJG-01685u1
 
Description
The National Cancer Institute (NCI)-Developmental Therapeutics Program (DTP) - Screening Technologies Branch (STB) seeks Cooperative Research and Development Agreement (CRADA) collaborator(s) to participate in the optimization of small molecule, molecular-targeted anticancer screening leads for potency and pharmaceutical properties consistent with clinical developmenta. The leads have been identified by the NCI-STB using high-throughput screening and preliminary structure/activity study of 140,000 samples from an NCI repository addressing a number of antitumor molecular targets of potential therapeutic significance. Potential Areas if Application: Antitumor agents. Specifically, opportunities are available to optimize antitumor leads for inhibition of Hypoxia Inducible Factor-1 (HIF-1) alpha signaling and for inducers of the CCAAT/Enhancer Binding Protein (CEBP- ) signaling pathway. Main Advantages of the Technology: Lead compounds possess distinct mechanisms of antitumor activities. Current State of Development: In vitro evaluation and preliminary structure/activity studies on-going at NCI for existing leads. Further R&D Requireda: Initially, a medicinal chemistry partner is sought to identify and resolve potential structural problems / features thus optimizing lead compound(s) for activity, potency, formulation, stability, metabolism, toxicity, absorption/distribution etc. Secondary or in vivo biological testing would be carried out by the NCI-Screening Technologies Branch. In a second stage, in vivo active compounds will be subjected to additional analysis and analogs will be synthesized to further optimize structure/activity properties. Pertinent References: Federal Register, November 8th, 2002, Volume 67, No. 217, pp. 68143-68144. "National Cancer Institute: Chemical Optimization of Molecular- Targeted Anticancer, Antiviral and Antimicrobial Drug Leads". Contact Information: Bjarne Gabrielsen, Ph.D., Technology Transfer Branch, NCI-Frederick, Fairview Center, Suite 500 1003 W. 7th Street, Frederick, MD 21701-8512. Phone: (301) 846-5465; email: bjg@nih.gov. Last Updated 11/10/2004
 
Record
SN00710700-W 20041121/041119211639 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.